BeiGene, Ltd. (NASDAQ:BGNE - Get Free Report) insider Xiaodong Wang sold 40,468 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
BeiGene Trading Up 4.3 %
Shares of BGNE stock traded up $8.84 during mid-day trading on Friday, reaching $215.00. The company's stock had a trading volume of 258,572 shares, compared to its average volume of 266,091. The firm has a market capitalization of $20.94 billion, a PE ratio of -26.09 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $248.16. The company's 50 day simple moving average is $212.42 and its 200-day simple moving average is $184.46.
BeiGene (NASDAQ:BGNE - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business's revenue was up 28.2% on a year-over-year basis. During the same period last year, the business earned $2.01 earnings per share. On average, research analysts predict that BeiGene, Ltd. will post -5.38 EPS for the current fiscal year.
Analysts Set New Price Targets
BGNE has been the topic of several research analyst reports. Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a research report on Thursday, August 8th. StockNews.com downgraded BeiGene from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. lifted their target price on BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd. JMP Securities began coverage on BeiGene in a research note on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 price objective for the company. Finally, TD Cowen boosted their target price on BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $247.07.
Check Out Our Latest Stock Analysis on BGNE
Hedge Funds Weigh In On BeiGene
Hedge funds have recently made changes to their positions in the business. Blue Trust Inc. raised its holdings in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after buying an additional 75 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in shares of BeiGene during the third quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BeiGene in the third quarter valued at approximately $67,000. SG Americas Securities LLC acquired a new position in BeiGene in the third quarter valued at approximately $105,000. Finally, PFG Investments LLC bought a new stake in shares of BeiGene in the 3rd quarter worth $210,000. Institutional investors and hedge funds own 48.55% of the company's stock.
About BeiGene
(
Get Free Report)
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeiGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeiGene wasn't on the list.
While BeiGene currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
